Tango Therapeutics, Inc. (TNGX) Form 8-K — Nov 9, 2026
Tango Therapeutics reported a Q3 2026 net loss of $68.4 million ($0.39/share) versus net income of $15.9 million a year ago, as collaboration revenue fell to zero following the August 2025 truncation of its Gilead partnership. The clinical story dominated the release: vopimetostat plus Revolution Medicines' daraxonrasib posted an 82% objective response rate and 88% nine-month progression-free survival in 2L/3L MTAP-deleted pancreatic cancer at ESMO.
Key figures
- Total Debt
- 0
- Total Assets
- 1033460000
- Cash Position
- 977500000
- Q3 2025 ga expense
- 8900000
- Q3 2026 ga expense
- 29200000
- Nine month pfs rate
- 88%
- Q3 2025 rnd expense
- 30800000
- Q3 2026 rnd expense
- 48900000
- Weighted avg shares q3 2025
- 110966345
- Weighted avg shares q3 2026
- 173930255
- Q3 2025 collaboration revenue
- 53800000
- Q3 2026 collaboration revenue
- 0
- Orr vopimetostat daraxonrasib 2l3l pdac
- 82%
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.